Pacira BioSciences, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending March 31, 2025: 2.87%

Pacira BioSciences, Inc. EBITDA Margin is 2.87% for the Trailing 12 Months (TTM) ending March 31, 2025, a -88.48% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.
  • Pacira BioSciences, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending March 31, 2024 was 24.89%, a 63.09% change year over year.
  • Pacira BioSciences, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending March 31, 2023 was 15.26%, a -50.11% change year over year.
  • Pacira BioSciences, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending March 31, 2022 was 30.59%, a 61.92% change year over year.
  • Pacira BioSciences, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending March 31, 2021 was 18.89%, a 49.18% change year over year.
Key Data
Date EBITDA Margin Net Income Margin EBT Margin Operating Income Margin